Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Trevena (TRVN) Resubmits NDA For Pain Drug Oliceridine To FDA

Published 02/10/2020, 09:22 PM
Updated 07/09/2023, 06:31 AM

Trevena, Inc. ( (NASDAQ:TRVN) announced the resubmission of its new drug application (NDA) to the FDA for its lead investigational product - IV oliceridine — for the management of moderate-to-severe acute pain.

Oliceridine is an opioid-based analgesic administered intravenous and also a G protein biased ligand of the mu receptor, which is being developed for managing moderate-to-severe acute pain.

In November 2018, the FDA issued a complete response letter (CRL) with respect to the company’s NDA for oliceridine. In the CRL, the FDA requested additional clinical data on the QT interval and indicated that the submitted safety database was not of adequate size for the proposed labeling. The FDA also requested certain additional nonclinical data and validation reports. In January 2019, the company announced the receipt of the official Type A meeting minutes from the FDA regarding the CRL, wherein the agency agreed that its current safety database will support labeling at a maximum daily dose of 27 mg. The resubmission package included data from the multi-dose healthy volunteer QT study, nonclinical data that confirmed levels of an inactive metabolite and drug product validation reports. The resubmission package also specified a maximum daily dose of 27 mg, as previously acknowledged by FDA in the Type A meeting minutes.

Shares of Trevena have slumped 50% in the past year compared with the industry’s decline of 1.3%.

Meanwhile, the company is also developing two G protein biased ligand candidates — TRV250 as a non-narcotic treatment for migraine in partnership with the National Institute on Drug Abuse (NIDA) and TRV734 for maintenance treatment of opioid use disorder .

Zacks Rank and Stocks to Consider

Currently, Trevena is a Zacks Rank #3 (Hold) stock.

A few better-ranked stocks in the biotech sector are Anavex Life Sciences Corp. (NASDAQ:AVXL) , Guardant Health Inc. (NASDAQ:GH) and Oncolytics Biotech Inc. (NASDAQ:ONCY) , all sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Anavex’s loss per share estimates have narrowed from 64 cents to 48 cents for 2020 and from 67 cents to 42 cents for 2021 in the past 90 days. The company delivered a positive earnings surprise in two of the trailing four quarters by 8.26%, on average.

Guardant’s loss per share estimates have narrowed from $1.18 to $1.13 for 2020 in the past 90 days. The company delivered a positive earnings surprise in the trailing four quarters by 39.21%, on average.

Oncolytics’ loss per share estimates have narrowed from 79 cents to 74 cents for 2019 and from 67 cents to 59 cents for 2020 in the past 60 days.

Zacks Top 10 Stocks for 2020

In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020? Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.

Access Zacks Top 10 Stocks for 2020 today >>



Oncolytics Biotech Inc. (ONCY): Free Stock Analysis Report

Trevena, Inc. (TRVN): Free Stock Analysis Report

Anavex Life Sciences Corp. (AVXL): Free Stock Analysis Report

Guardant Health, Inc. (GH): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.